{ "as_of": "2026-11-01", "track": "hdac", "programs": [ { "id": "hdac-abt301", "asset_id": "Anbogen Therapeutics::ABT-301 / MPT0E028", "company_id": "co-3560cdae4f370ef8", "company": "Anbogen Therapeutics", "company_zh": "安邦生技股份有限公司", "country": "Taiwan", "country_basis": "Taiwan", "code": "ABT-301", "asset": "ABT-301 / MPT0E028", "mechanism": "Class I and IIb", "stage": "Phase 1b/2", "stage_detail": "Phase 1b/2 (registry phases 1/2), recruiting; pMMR/non-MSI-H advanced/metastatic CRC + tislelizumab + bevacizumab (NCT07244705).", "stage_detail_zh": "第 1b/2 期（登錄為第 1/2 期）、招募中；pMMR/non-MSI-H 晚期／轉移性大腸直腸癌，併用 tislelizumab 與 bevacizumab（NCT07244705）。", "indication": null, "partner": null, "terms": null, "sources": [ { "id": "anbogen_update", "url": "https://anbogen.com/en/news/89FDfa469DeC", "source_date": "2026-10-05", "accessed_on": "2026-11-01", "title": "Anbogen clinical update at Chang Gung Medical Week", "observation": "ABT-301 Class I/IIb HDAC inhibitor; phase 1b/2 pMMR/non-MSI-H CRC triplet. Cutoff Sep 30: 10 QD participants, no DLT; separate six BID participants had three DLTs. Treatment duration is not validated efficacy. Taiwan company.", "locator": "Paragraphs on ABT-301; Part 1 cohorts; efficacy limitation", "retrieval": "direct public GET; claim observed in primary-source web extraction; receipt in source_http_receipts.json" }, { "id": "ctg_NCT07244705", "url": "https://clinicaltrials.gov/study/NCT07244705", "source_date": "2025-11-24", "accessed_on": "2026-11-01", "title": "A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC", "observation": "Registry status RECRUITING; phases PHASE1, PHASE2; lead sponsor Anbogen Therapeutics, Inc.", "locator": "protocolSection.identificationModule; statusModule; designModule; sponsorCollaboratorsModule; descriptionModule", "retrieval": "original ClinicalTrials.gov v2 API JSON" } ], "source_date": "2026-10-05" }, { "id": "hdac-purinostat", "asset_id": "Chengdu Zenitar Biomedical Technology::Purinostat mesylate", "company_id": "co-4d1084c565f345d6", "company": "Chengdu Zenitar Biomedical Technology", "company_zh": null, "country": "China", "country_basis": "China", "code": "Purinostat mesylate", "asset": "Purinostat mesylate", "mechanism": "Classes I and IIb-selective", "stage": "Phase 3", "stage_detail": "Phase 3, recruiting: purinostat mesylate vs selinexor in relapsed/refractory DLBCL (NCT07011056).", "stage_detail_zh": "第 3 期、招募中：purinostat mesylate 對照 selinexor，治療復發／難治型 DLBCL（NCT07011056）。", "indication": null, "partner": null, "terms": null, "sources": [ { "id": "purinostat_paper", "url": "https://www.nature.com/articles/s41392-025-02285-w", "source_date": "2025-06-23", "accessed_on": "2026-11-01", "title": "Purinostat preclinical and first-in-human original research", "observation": "Purinostat mesylate selectively inhibits HDAC classes I and IIb. Phase 1 study NCT05526313; newer phase 3 status comes from registry.", "locator": "Title; abstract; publication date", "retrieval": "direct public GET; claim observed in primary-source web extraction; receipt in source_http_receipts.json" }, { "id": "ctg_NCT07011056", "url": "https://clinicaltrials.gov/study/NCT07011056", "source_date": "2025-09-19", "accessed_on": "2026-11-01", "title": "A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma", "observation": "Registry status RECRUITING; phases PHASE3; lead sponsor Chengdu Zenitar Biomedical Technology Co., Ltd", "locator": "protocolSection.identificationModule; statusModule; designModule; sponsorCollaboratorsModule; descriptionModule", "retrieval": "original ClinicalTrials.gov v2 API JSON" } ], "source_date": "2025-09-19" }, { "id": "hdac-chidamide", "asset_id": "Chipscreen Biosciences::Tucidinostat / chidamide / Epidaza", "company_id": "co-aa8f22ba36963d67", "company": "Chipscreen Biosciences", "company_zh": null, "country": "China", "country_basis": "China", "code": "Tucidinostat", "asset": "Tucidinostat / chidamide / Epidaza", "mechanism": "Class I (HDAC1/2/3) and IIb (HDAC10)-selective", "stage": "Approved", "stage_detail": "China: PTCL (2014), HR+/HER2− advanced breast cancer with endocrine therapy (2019), untreated MYC/BCL2-positive DLBCL + R-CHOP (2024). Japan: ATL and PTCL (2021). Taiwan: breast cancer + exemestane (2023).", "stage_detail_zh": "中國核准 PTCL（2014）、HR+/HER2− 晚期乳癌合併內分泌治療（2019），以及未治療 MYC/BCL2 陽性 DLBCL 合併 R-CHOP（2024）；日本核准 ATL 與 PTCL（2021）；台灣核准乳癌合併 exemestane（2023）。", "indication": null, "partner": null, "terms": null, "sources": [ { "id": "chips_dlbcl", "url": "https://www.chipscreen.com/en/news/company-news/1284.html", "source_date": "2024-04-30", "accessed_on": "2026-11-01", "title": "Chipscreen DLBCL approval announcement", "observation": "Chidamide with R-CHOP approved for previously untreated MYC/BCL2-positive DLBCL. Confirms prior China, Japan and Taiwan approvals. Shenzhen company address.", "locator": "Announcement and global commercialisation list", "retrieval": "direct public GET; claim observed in primary-source web extraction; receipt in source_http_receipts.json" }, { "id": "chips_latest", "url": "https://www.chipscreen.com/en/news/company-news/1477.html", "source_date": "2026-04-23", "accessed_on": "2026-11-01", "title": "Chipscreen DEB phase 3 publication announcement", "observation": "Company reports full phase 3 DEB publication in JAMA on April 23, 2026; candidate uses publication event only, without comparative efficacy numbers.", "locator": "Dated opening paragraph", "retrieval": "direct public GET; claim observed in primary-source web extraction; receipt in source_http_receipts.json" }, { "id": "chips_mechanism", "url": "https://pubmed.ncbi.nlm.nih.gov/22080169/", "source_date": "2011-11-12", "accessed_on": "2026-11-01", "title": "Original chidamide CS055/HBI-8000 pharmacology study", "observation": "Original recombinant-enzyme experiments identify HDAC1, HDAC2, HDAC3 and HDAC10 inhibition. Chipscreen affiliation in Shenzhen, China.", "locator": "Results; affiliation; Epub date", "retrieval": "direct public GET; claim observed in primary-source web extraction; receipt in source_http_receipts.json" } ], "source_date": "2026-04-23" }, { "id": "hdac-entinostat", "asset_id": "Syndax; Taizhou EOC Pharma / Edding Genor (China)::Entinostat / SNDX-275 / MS-275", "company_id": "co-479c2ecf61132376", "company": "Syndax; Taizhou EOC Pharma / Edding Genor (China)", "company_zh": null, "country": "China", "country_basis": "United States; China", "code": "Entinostat", "asset": "Entinostat / SNDX-275 / MS-275", "mechanism": "Class I-selective", "stage": "Approved", "stage_detail": "China approved (April 2024): HR+/HER2− locally advanced or metastatic breast cancer progressing after endocrine therapy, with an aromatase inhibitor. Syndax has deprioritised development.", "stage_detail_zh": "中國於 2024-04 核准：內分泌治療後進展的 HR+/HER2− 局部晚期或轉移性乳癌，併用芳香化酶抑制劑；Syndax 已降低此開發計畫優先度。", "indication": null, "partner": null, "terms": null, "sources": [ { "id": "entinostat_approval", "url": "https://ir.syndax.com/static-files/441997e4-6c14-4abc-ae4f-2e23463f7ef4", "source_date": "2026-02-26", "accessed_on": "2026-11-01", "title": "Syndax 2025 Form 10-K", "observation": "China marketing approval April 2024; Syndax development deprioritised while Eddingpharm licence maintained. US company.", "locator": "Entinostat; collaboration/licence disclosures", "retrieval": "indexed primary-source excerpt from web search; direct GET failed or not stored; full text not independently accepted" }, { "id": "entinostat_commercial", "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0415/2026041500350.pdf", "source_date": "2026-04-15", "accessed_on": "2026-11-01", "title": "Edding Genor annual report 2025", "observation": "Entinostat in combination with aromatase inhibitors for HR-positive/HER2-negative locally advanced/metastatic breast cancer progressing after endocrine therapy. China commercial rights from Taizhou EOC; NRDL inclusion effective January 2026.", "locator": "Jing Zhu Da business highlights, printed page 10", "retrieval": "direct public GET; claim observed in primary-source web extraction; receipt in source_http_receipts.json" } ], "source_date": "2026-04-15" }, { "id": "hdac-abexinostat", "asset_id": "Xynomic Pharmaceuticals::Abexinostat / PCI-24781", "company_id": "co-333f99ca02bcec60", "company": "Xynomic Pharmaceuticals", "company_zh": null, "country": "China", "country_basis": "United States; China", "code": "Abexinostat", "asset": "Abexinostat / PCI-24781", "mechanism": "Pan-HDAC (HDAC1/2/3/6/10)", "stage": "Phase 3", "stage_detail": "Phase 3 RENAVIV, recruiting: abexinostat + pazopanib in advanced/metastatic RCC (NCT03592472).", "stage_detail_zh": "RENAVIV 第 3 期、招募中：abexinostat 合併 pazopanib 治療晚期／轉移性腎細胞癌（NCT03592472）。", "indication": null, "partner": null, "terms": null, "sources": [ { "id": "abex_filing", "url": "https://xynomicpharma.com/wp-content/uploads/2017/02/XynomicPharmaceuticalsHoldingsInc_07112019_S-1.pdf", "source_date": "2019-07-11", "accessed_on": "2026-11-01", "title": "Xynomic S-1 hosted by issuer", "observation": "Company acquired worldwide abexinostat rights in 2017. Pan-HDAC activity includes HDAC1/2/3/6/10. US corporate address; China development entity also documented in original 2026 study. This filing is historical.", "locator": "Business overview and corporate address", "retrieval": "indexed primary-source excerpt from web search; direct GET failed or not stored; full text not independently accepted" }, { "id": "abex_paper", "url": "https://www.nature.com/articles/s41392-026-02646-z", "source_date": "2026", "accessed_on": "2026-11-01", "title": "Abexinostat pivotal phase 2 original report", "observation": "Original report identifies Xynomic Pharmaceuticals (Nanjing), China, as abexinostat manufacturer. Candidate does not infer a marketing approval from phase 2 publication.", "locator": "Study drug and affiliations; precise day not transcribed", "retrieval": "direct public GET; claim observed in primary-source web extraction; receipt in source_http_receipts.json" }, { "id": "ctg_NCT03592472", "url": "https://clinicaltrials.gov/study/NCT03592472", "source_date": "2025-04-13", "accessed_on": "2026-11-01", "title": "A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)", "observation": "Registry status RECRUITING; phases PHASE3; lead sponsor Xynomic Pharmaceuticals, Inc.", "locator": "protocolSection.identificationModule; statusModule; designModule; sponsorCollaboratorsModule; descriptionModule", "retrieval": "original ClinicalTrials.gov v2 API JSON" } ], "source_date": "2026" } ], "deals": [] }